ACADIA Pharmaceuticals Inc.
ACADNASDAQHealthcare● Active
$21.40
$-0.16(-0.74%)
Market Cap$3.7B
P/E Ratio—
52W High$28.35
52W Low$19.69
ACADIA Pharmaceuticals Inc. (ACAD) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ACAD · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
$0.02
Est. $0.04 · -50.0%
Revenue
$0.27B
Est. $0.28B · -4.3%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
ACAD reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | $0.06 | — | — | — | $0.30B | — |
| ▼ Q2 FY2026 | May 6, 2026 | $0.04 | $0.02 | -50.0% | $0.27B | $0.28B | -4.3% |
| ▲ Q1 FY2026 | Feb 25, 2026 | $0.14 | $1.60 | +1067.9% | $0.28B | $0.29B | -3.0% |
| ▲ Q4 FY2025 | Nov 5, 2025 | $0.14 | $0.26 | +85.7% | $0.28B | $0.29B | -4.8% |
| ▲ Q3 FY2025 | Aug 6, 2025 | $0.14 | $0.16 | +14.3% | $0.26B | $0.26B | +1.0% |
| ▲ Q2 FY2025 | May 7, 2025 | $0.10 | $0.11 | +10.0% | $0.24B | $0.24B | +2.2% |
| ▲ Q1 FY2025 | Feb 26, 2025 | $0.13 | $0.17 | +30.8% | $0.26B | $0.27B | -4.9% |
| ▲ Q4 FY2024 | Nov 6, 2024 | $0.14 | $0.20 | +42.9% | $0.25B | $0.28B | -11.5% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
$0.06
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 6, 2026Miss
EPS Actual
$0.02
EPS Est.
$0.04
EPS Surpr.
-50.0%
Revenue
$0.27B
Q1 FY2026
Feb 25, 2026Beat
EPS Actual
$1.60
EPS Est.
$0.14
EPS Surpr.
+1067.9%
Revenue
$0.28B
Q4 FY2025
Nov 5, 2025Beat
EPS Actual
$0.26
EPS Est.
$0.14
EPS Surpr.
+85.7%
Revenue
$0.28B
Q3 FY2025
Aug 6, 2025Beat
EPS Actual
$0.16
EPS Est.
$0.14
EPS Surpr.
+14.3%
Revenue
$0.26B
Q2 FY2025
May 7, 2025Beat
EPS Actual
$0.11
EPS Est.
$0.10
EPS Surpr.
+10.0%
Revenue
$0.24B
Q1 FY2025
Feb 26, 2025Beat
EPS Actual
$0.17
EPS Est.
$0.13
EPS Surpr.
+30.8%
Revenue
$0.26B
Q4 FY2024
Nov 6, 2024Beat
EPS Actual
$0.20
EPS Est.
$0.14
EPS Surpr.
+42.9%
Revenue
$0.25B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.25 | $0.26 | $0.27 | 3 |
| Q3 FY2027 | $0.23 | $0.24 | $0.25 | 4 |
| Q2 FY2027 | $0.20 | $0.21 | $0.22 | 3 |
| Q1 FY2027 | $0.19 | $0.20 | $0.21 | 3 |
| Q4 FY2026 | $0.17 | $0.18 | $0.19 | 7 |
| Q3 FY2026 | $0.10 | $0.13 | $0.17 | 9 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.4B | $0.4B | $0.4B | 6 |
| Q3 FY2027 | $0.4B | $0.4B | $0.4B | 6 |
| Q2 FY2027 | $0.3B | $0.3B | $0.4B | 6 |
| Q1 FY2027 | $0.3B | $0.3B | $0.3B | 6 |
| Q4 FY2026 | $0.3B | $0.4B | $0.4B | 11 |
| Q3 FY2026 | $0.3B | $0.3B | $0.3B | 12 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 6, 2026 | -50.0% | $22.35 | $21.48 | -3.89% |
| ▲ Q1 FY2026 | Feb 25, 2026 | +1067.9% | $24.59 | $24.97 | +1.55% |
| ▲ Q4 FY2025 | Nov 5, 2025 | +85.7% | $21.85 | $22.33 | +2.20% |
| ▲ Q3 FY2025 | Aug 6, 2025 | +14.3% | $23.64 | $23.80 | +0.68% |
| ▲ Q2 FY2025 | May 7, 2025 | +10.0% | $14.54 | $14.81 | +1.86% |
| ▲ Q1 FY2025 | Feb 26, 2025 | +30.8% | $19.01 | $19.00 | -0.05% |
| ▲ Q4 FY2024 | Nov 6, 2024 | +42.9% | $15.00 | $15.79 | +5.27% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +11.1% | $18.41 | $18.85 | +2.39% |
Q2 FY2026-3.89%
Report Date
May 6, 2026
EPS Beat/Miss
-50.0%
Price Before
$22.35
Price After
$21.48
Q1 FY2026+1.55%
Report Date
Feb 25, 2026
EPS Beat/Miss
+1067.9%
Price Before
$24.59
Price After
$24.97
Q4 FY2025+2.20%
Report Date
Nov 5, 2025
EPS Beat/Miss
+85.7%
Price Before
$21.85
Price After
$22.33
Q3 FY2025+0.68%
Report Date
Aug 6, 2025
EPS Beat/Miss
+14.3%
Price Before
$23.64
Price After
$23.80
Q2 FY2025+1.86%
Report Date
May 7, 2025
EPS Beat/Miss
+10.0%
Price Before
$14.54
Price After
$14.81
Q1 FY2025-0.05%
Report Date
Feb 26, 2025
EPS Beat/Miss
+30.8%
Price Before
$19.01
Price After
$19.00
Q4 FY2024+5.27%
Report Date
Nov 6, 2024
EPS Beat/Miss
+42.9%
Price Before
$15.00
Price After
$15.79
Q3 FY2024+2.39%
Report Date
Aug 6, 2024
EPS Beat/Miss
+11.1%
Price Before
$18.41
Price After
$18.85
Avg Beat Reaction+1.99%
Avg Miss Reaction-3.89%
Beat Rate7 / 8 quarters
Largest Move+5.27% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ACAD ends December
ACADIA Pharmaceuticals Inc. (ACAD) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $0.02 — missing the analyst consensus of $0.04 by -50.0%. The next ACAD earnings date is expected around September 1, 2026.
Each quarter, investors track ACAD earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ACAD revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ACAD's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ACAD earnings · 5 questionsACADIA Pharmaceuticals Inc.'s next earnings report is expected around September 1, 2026. ACAD typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ACAD historically reports after market close (AMC).
ACAD earnings datewhen is ACAD earningsACAD next earnings datewhen does ACAD report earningsACAD earnings calendar
▸ Source: FMP · ACADIA Pharmaceuticals Inc. SEC filings · US GAAP · ACADIA Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026